American Heart Association, Nov. 16-18

Follow Drugslib on

Medically reviewed by Drugs.com.

By Beth Gilbert HealthDay Reporter

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. The conference featured presentations focusing on the latest advances in cardiovascular medicine and surgery.

In one study, Lucas X. Marinacci, M.D., of the Beth Israel Deaconess Medical Center in Boston, and colleagues found that cardiovascular mortality increased among rural areas and decreased among urban areas between 2010 and 2022, leading to a widening of rural-urban disparities in cardiovascular death rates.

Pulling information from the U.S. Centers for Disease Control and Prevention WONDER database, national mortality data for more than 11 million adults between 2010 and 2022 were evaluated.

The researchers observed an increase in cardiovascular mortality nationwide after the pandemic, which disproportionately impacted rural areas. In addition, there was notably a concerning rise in cardiovascular mortality among younger (25 to 64 years) rural adults before the pandemic that then accelerated in its wake. Furthermore, differences in poverty, education, and insurance coverage accounted for a substantial portion of rural-urban differences in cardiovascular mortality as of 2022.

"One key takeaway is that targeted policy efforts are needed to address rising cardiovascular mortality in rural areas, especially among younger age groups," Marinacci said. "This can include initiatives to increase insurance coverage, such as by expanding Medicaid under the Affordable Care Act in states that have yet to do so; improving health care access, such as by preventing hospital closures; bolstering the rural health care workforce and expanding telemedicine reimbursement; addressing the surge in severe obesity and its downstream cardiometabolic consequences through concerted public health campaigns; and, finally, addressing the underlying socioeconomic determinants of health -- including educational attainment and poverty -- that are strongly linked to adverse cardiovascular outcomes."

Press Release

In another study, M. Ali Sheffeh, M.D., of the Mayo Clinic in Rochester, Minnesota, and colleagues found that patients with a previous stroke who are prescribed either a glucagon-like peptide-1 (GLP-1) receptor agonist or a sodium-glucose cotransporter 2 (SGLT2) inhibitor have a reduced risk for a heart attack, second stroke, and death.

The authors conducted a retrospective study between 2000 and 2022 and included all patients who had a stroke in parts of Minnesota and Wisconsin. The effect of using these two different diabetes medications (SGLT2i and GLP-1 RA) on the risk for death or having a future heart attack or another stroke was then evaluated. The researchers discovered that patients who took one of these medications had a lower risk for death or experiencing a heart attack or another stroke.

"Our findings won't change the current clinical practice; however, they represent an important step toward further evaluating the benefits of these medications in diverse patient populations," Sheffeh said.

One author disclosed financial ties to WizeCare, Novo Nordisk, and Kento Health.

Press Release

As part of the ASPirin in Reducing Events in the Elderly (ASPREE) study, Zhen Zhou, Ph.D., of Monash University in Melbourne, Australia, and colleagues found that individuals with more pronounced year-to-year fluctuations in cholesterol levels have an increased risk for cognitive decline.

The investigators evaluated in-trial and posttrial data for participants enrolled in the ASPREE study and found that individuals with greater year-to-year fluctuations in cholesterol levels had a higher risk for developing dementia and cognitive decline. As such, patients with substantial cholesterol fluctuations over years unrelated to medication use may warrant closer monitoring of dementia risk and other health conditions associated with increased dementia risk. In contrast, no correlation was observed between average blood cholesterol levels over the lipid measurement period and subsequent dementia risk.

"These findings underscore the importance of monitoring cholesterol level variation as a potential predictor of dementia risk, rather than solely relying on a one-off cholesterol measurement," Zhou said.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Press Release

AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent

TUESDAY, Nov. 26, 2024 -- From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor for patients with heart failure and a left ventricular ejection fraction greater than 40 percent, according to a study published online Nov. 18 in JAMA Cardiology to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Bumetanide Nasal Spray Statistically Bioequivalent to Oral Bumetanide

MONDAY, Nov. 25, 2024 -- Bumetanide nasal spray has statistical bioequivalence to oral bumetanide, according to a research letter published online Nov. 18 in Circulation to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk

MONDAY, Nov. 25, 2024 -- Muvalaplin reduces lipoprotein(a) levels, according to a study published online Nov. 20 in the Journal of the American Medical Association to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia

FRIDAY, Nov. 22, 2024 -- An initial strategy of catheter ablation leads to a lower risk for a composite primary end point than antiarrhythmic drug therapy among patients with ischemic cardiomyopathy and ventricular tachycardia, according to a study published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity

FRIDAY, Nov. 22, 2024 -- For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure, according to a study published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide

FRIDAY, Nov. 22, 2024 -- More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Intensive Strategy for Lowering Systolic BP Beneficial in Type 2 Diabetes

WEDNESDAY, Nov. 20, 2024 -- For patients with type 2 diabetes and elevated systolic blood pressure, an intensive-treatment strategy is better than a standard-treatment strategy for incidence of major cardiovascular disease events, according to a study published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Rising Outdoor Temperatures Tied to Higher Risk for Atrial Fibrillation

MONDAY, Nov. 18, 2024 -- There is a dose-response relationship between rising outdoor temperatures and increased atrial fibrillation events, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: AI Analysis of Images, Videos Can ID Early Hypertension, Diabetes

MONDAY, Nov. 18, 2024 -- Machine learning analysis of photo and video data demonstrates a promising way to noninvasively detect early hypertension and diabetes, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Rural-Urban Disparities Persist in Cardiovascular Mortality

FRIDAY, Nov. 15, 2024 -- Between 2010 and 2022, cardiovascular mortality increased in rural areas and decreased in urban areas, according to a study scheduled for presentation at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: More Moderate-to-Vigorous Exercise Tied to Lower Risk for A-Fib

THURSDAY, Nov. 14, 2024 -- Higher amounts of moderate-to-vigorous physical activity are inversely associated with a lower risk for incident atrial fibrillation, according to a study scheduled for presentation at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: Obesity-Linked Ischemic Heart Disease Mortality Increasing in U.S.

WEDNESDAY, Nov. 13, 2024 -- In the United States, obesity-related ischemic heart disease mortality is increasing, with the highest rates seen among men, Blacks, and those in the Midwest, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors

TUESDAY, Nov. 12, 2024 -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are associated with reduced mortality, myocardial infarction, and recurrent stroke, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Read Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-28 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords